← Back to Patent Explorer
US4778879A Expired / Lapsed US ⏱️ 0.0 years remaining

Highly purified human interleukin 2 and method

Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1984-04-25
•
Granted: 1988-10-18
•
Expires: 2004-04-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH4)2SO4-precipitation, ion-exchange chromatography, gel filtration and hydrophobic chromatography. hp IL-2 is free of pyrogens, B cell inducing factor, B cell growth factor, interferon, CSF, and thymocyte differentiating factor. Nature IL 2 produced in the absence of Daudi cells has a molecular weight of about 26,000 daltons as measured by gel filtration and yields IL 2 having two molecular weights of about 16,000 and 17,000 daltons after denaturation as measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IL 2 produced in the presence of Daudi cells shows a molecular weight of approximately 14,500 daltons as measured by both gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This highly purified IL 2 is shown to correct immunodeficiency states in vitro and in vivo, especially in human patients. It shows value in the treatment of AIDS and immunodeficiency resulting from chemotherpy of cancer, as well as transplantation disorders such as graft versus host disease.

Inventors

  • 👤 Roland Mertelsmann
  • 👤 Karl Welte
  • 👤 Salvatore Venuta

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 02:59
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 53 words
Native highly purified human IL-2 wherein said IL-2 is obtained from normal peripheral lymphocytes is purified over 37,000 fold and exhibits pharmacological activity in humans and has a specific activity of at least 10 6 ±10% U/mg and a threshold concentration for biological activity no greater than 0.2±0.05 U/ml and wherein the IL-2:
Claim 2
Dependent Claim 53 words
Native highly purified human IL-2 wherein said IL-2 is obtained from normal peripheral lymphocytes is purified over 37,000 fold and exhibits pharmacological activity in humans and has a specific activity of at least 10 6 ±10% U/mg and a threshold concentration for biological activity no greater than 0.2±0.05 U/ml and wherein the IL-2:
Claim 3
Dependent Claim 117 words
(1) has a relative molecular weight of 26000±4000 daltons with an isoelectric point of pH 6.7±0.2 when produced in the absence of Daudi cells which IL-2 material when denatured exhibits a relative molecular weight of 16,000±1,000 or 17,000±1,000 daltons, (2) has a relative molecular weight of 14,500±2000 daltons with an isoelectric point of pH 8.1±0.02 when produced in the presence of Daudi cells, (3) is pyrogen free, (4) is free of contaminants selected from the group consisting of B-cell growth factor (BGF), B-cell inducing factor (BIF), alpha or gamma interferon (IFN), granulocyte-macrophage colony-stimulating factor (CSF) and thymocyte differentiating activity, and (5) is free of proteinaceous contaminant when assayed by the silver nitrate or I 125 exolabeling methods.
Claim 4
Dependent Claim 117 words
(1) has a relative molecular weight of 26000±4000 daltons with an isoelectric point of pH 6.7±0.2 when produced in the absence of Daudi cells which IL-2 material when denatured exhibits a relative molecular weight of 16,000±1,000 or 17,000±1,000 daltons, (2) has a relative molecular weight of 14,500±2000 daltons with an isoelectric point of pH 8.1±0.02 when produced in the presence of Daudi cells, (3) is pyrogen free, (4) is free of contaminants selected from the group consisting of B-cell growth factor (BGF), B-cell inducing factor (BIF), alpha or gamma interferon (IFN), granulocyte-macrophage colony-stimulating factor (CSF) and thymocyte differentiating activity, and (5) is free of proteinaceous contaminant when assayed by the silver nitrate or I 125 exolabeling methods.

References Cited (Backward Citations)

US4490289A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-10-18 1992-04-18 1992-10-18 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-10-18 1996-04-18 1996-10-18 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-10-18 2000-04-18 2000-10-18 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag